Abstract
Background: Two female breast cancer patients developed epiphora after administration of cyclophosphamide and/or anthracyclines based 2-day chemotherapy regimen. An ophthalmologist was consulted and no apparent cause was found.
Case Description: Patients were managed by ciprofloxacin eye drops. Chemotherapy induced ocular complications are not uncommon, but under reported. Although epiphora is a mild reaction, if severe however, it can interfere with daily activities. Patients having chemotherapy induced ocular toxicity should go for ophthalmic examination to pick up ocular adverse effects of anticancer drugs and treat them at an early stage.
Keywords: Cyclophosphamide, anthracyclines, epiphora, chemotherapy, ophthalmic examination, ocular adverse effects.
Graphical Abstract
Current Drug Safety
Title:Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect
Volume: 13 Issue: 1
Author(s): Ruchika Kalra, Bhavesh Chavada, Nishant R. Madhani, Bhargav Purohit*C.B. Tripathi
Affiliation:
- Department of Pharmacology, Government Medical College and Sir Takhtsinhji General Hospital, Bhavnagar-364001 (Gujarat),India
Keywords: Cyclophosphamide, anthracyclines, epiphora, chemotherapy, ophthalmic examination, ocular adverse effects.
Abstract: Background: Two female breast cancer patients developed epiphora after administration of cyclophosphamide and/or anthracyclines based 2-day chemotherapy regimen. An ophthalmologist was consulted and no apparent cause was found.
Case Description: Patients were managed by ciprofloxacin eye drops. Chemotherapy induced ocular complications are not uncommon, but under reported. Although epiphora is a mild reaction, if severe however, it can interfere with daily activities. Patients having chemotherapy induced ocular toxicity should go for ophthalmic examination to pick up ocular adverse effects of anticancer drugs and treat them at an early stage.
Export Options
About this article
Cite this article as:
Kalra Ruchika , Chavada Bhavesh, Madhani R. Nishant, Purohit Bhargav*, Tripathi C.B., Cyclophosphamide and/or Anthracyclines Induced Epiphora in Breast Cancer Patients: A Rare Side-effect, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886312666170919175614
DOI https://dx.doi.org/10.2174/1574886312666170919175614 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Current Highlights About the Safety of Inorganic Nanomaterials in Healthcare
Current Medicinal Chemistry Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry New Platinum (II) Ternary Complexes of Formamidine and Pyrophosphate: Synthesis, Characterization and DFT Calculations and <i>In vitro</i> Cytotoxicity
Combinatorial Chemistry & High Throughput Screening Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine Therapeutic Value of an Integrin Antagonist in Prostate Cancer
Current Drug Targets In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Tracking Cell Signaling Protein Expression and Phosphorylation by Innovative Proteomic Solutions
Current Pharmaceutical Biotechnology WNT Signaling in Stem Cell Biology and Regenerative Medicine
Current Drug Targets Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry Immunomodulating and Anti-Allergic Effects of Negroamaro and Koshu Vitis vinifera Fermented Grape Marc (FGM)
Current Pharmaceutical Design Antineoplastic and Antimicrobial Potential of Novel Phytofabricated Silver Nanoparticles from <i>Pterospermum acerifolium</i> Leaf Extract
Nanoscience & Nanotechnology-Asia MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design